Emergent BioSolutions (EBS) Experiences Stock Surge After Unveiling Expansion Move
Following an announcement of an expansion move, Emergent BioSolutions Inc. (NYSE: EBS) stock experienced a notable surge on Thursday. EBS shares rose 46.85%, to conclude at $8.40, driven by heightened investor enthusiasm. This upward trajectory reflects a positive market reaction to Emergent’s strategic moves. Enhancing Access and Commitment Emergent BioSolutions (EBS) has demonstrated its commitment […]
Emergent BioSolutions Inc. (EBS) stock soars during pre-market session. Here’s what’s happening?
Emergent BioSolutions Inc. (NASDAQ: EBS) stock gained by 0.61% at last close while the EBS stock price continued to rise by 5.54% in the pre-market trading session. Emergent BioSolutions, based in Gaithersburg, Maryland, is an international speciality biopharmaceutical firm. It creates vaccinations and antibody therapies for infectious illnesses and opioid overdoses, as well as biodefense […]
Emergent BioSolutions [EBS] Downgraded to Equal-Weight at Wells Fargo
Wells Fargo took its Emergent BioSolutions [EBS] rating to the equivalent of Equal-Weight from Overweight, in a research note dated 2021-01-08. Meanwhile, Chardan Capital Markets had maintained its rating on EBS to the earlier “Buy” rating, in a research note produced for clients July 31, 2020. In addition, Guggenheim launched coverage on September 12, 2019. […]
